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Abstract
Background: The mixed-lineage kinase (MLK) family member DLK has been proposed to serve as a regulator of
differentiation in various cell types; however, its role in adipogenesis has not been investigated. In this study, we used the
3T3-L1 preadipocyte cell line as a model to examine the function of DLK in adipocyte differentiation.
Methods and Findings: Immunoblot analyses and kinase assays performed on 3T3-L1 cells showed that the expression and
activity of DLK substantially increase as differentiation occurs. Interestingly, DLK appears crucial for differentiation since its
depletion by RNA interference impairs lipid accumulation as well as expression of the master regulators of adipogenesis C/
EBPa and PPARc2 at both the mRNA and protein levels. In contrast, neither the expression nor the DNA binding activity of
C/EBPb, an activator for C/EBPa and PPARc, is affected by DLK loss.
Conclusions: Taken together, these results suggest that DLK is important for expression of mature adipocyte markers and
that its action most likely takes place via regulation of C/EBPb transcriptional activity and/or initiation of C/EBPa and PPARc2
gene transcription.
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Introduction
Adipose tissue, the main organ for energy storage and
expenditure, secretes a variety of factors that maintain normal
body metabolism [1]. Its accumulation, however, can result in
obesity, which is a major risk factor for diseases such as diabetes
and hypertension [2–6]. Change in adipose mass can arise from an
increase in the size and the number of fat cells or adipocytes, the
latter being accomplished by the proliferation of preadipocytes
and their subsequent differentiation into mature adipocytes [7].
Due to the availability of preadipocyte cell lines such as 3T3-L1
and 3T3-F422A [8], which can be efficiently induced to undergo
terminal differentiation when exposed to the appropriate adipo-
genic hormones, considerable progress in our understanding of
adipocyte biology has been achieved in the past few years. Indeed,
the process of adipocyte differentiation is governed by a tightly
regulated cascade of transcription factors that are either activated
or repressed at specific times during differentiation [9–11]. These
variations in expression or activation lead to differential gene
expression that will eventually guide precursor cells through their
differentiation in adipocytes. Important members of this genetic
cascade are the CCAAT/enhancer binding proteins (C/EBP)
family members C/EBPb and C/EBPd, which are highly
expressed early during differentiation [12]. C/EBPb and C/EBPd
then elicit the expression of C/EBPa and the PPARc (Peroxisome
proliferator-activated receptor c) isoform PPARc2, two transcrip-
tion factors working in a cooperative manner to promote the
expression of various adipocyte-specific genes [13]. Their ability to
control the expression of genes responsible for glucose trafficking
and mature adipocyte metabolism [11] indeed place them as key
factors of adipocyte differentiation.
Besides transcription factors, a variety of extracellular and
intracellular signaling molecules are also known to play key roles in
adipocyte differentiation [11,14–17]. Of particular interest to this
study is the demonstration that mitogen-activated protein kinases
(MAPKs) [18], which include extracellular signal-regulated kinases
(ERKs), p38 kinases and c-Jun N-terminal kinases (JNKs),
modulate either positively or negatively adipogenesis as a result
of their ability to regulate the proadipogenic transcription factors
C/EBPb and PPARc [19,20]. Recently, it has also been shown
that MLK3, a JNK activator belonging to the mixed-lineage
kinase (MLK) subgroup of MAPK kinase kinase (MAPKKK),
plays a role in adipocyte differentiation [21]. Support for this
notion derives from the observation that the expression and
phosphorylation of C/EBPa and C/EBPb were significantly
increased at early times during differentiation of mouse embryonic
fibroblasts (MEF) deficient in Mlk3 (MLK3
2/2). Furthermore, it
was found that MLK3
2/2 cells accumulate more lipids than wild-
type MEF and that overexpression of MLK3 in these cells
inhibited adipogenic differentiation.
In contrast to MLK3, which is widely expressed in many tissues
[21], the MLK family member dual leucine zipper-bearing kinase
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4743(DLK) exhibits a more restricted pattern of expression [22,23].
During development, expression of DLK mRNA has been
primarily detected in neuronal tissues such as brain and spinal
ganglion, as well as in the epithelia of the skin, intestine, pancreas,
and kidney [22]. In all these tissues, the expression of DLK mRNA
increases with development and correlates with areas undergoing
terminal cell differentiation. Consistent with a causal role for DLK
in differentiation, ectopic expression of DLK in normal human
keratinocytes promotes their terminal differentation, as evidenced
by up-regulation of filaggrin, DNA fragmentation and activation
of transglutaminases [24]. Based on these observations, it thus
appears likely that DLK may fulfill specific signaling functions
required in either the induction or the maintenance of the
differentiated state for a wide variety of cell populations. In
keeping with this hypothesis, we demonstrate herein that DLK is
expressed in mouse adipose tissue and that its expression
dramatically increases during adipogenic differentiation of 3T3-
L1 cells. In addition, our results show that 3T3-L1 cells depleted in
DLK by specific shRNA failed to accumulate lipids or express C/
EBPa and the adipocyte-specific PPARc2 isoform in response to
adipogenic stimuli. Finally, we provide evidence that DLK
depletion does not perturb the ability of C/EBPb to bind to the
c/ebpa and pparc2 promoters, indicating that DLK acts upstream
of the master adipogenesis regulators C/EBPa and PPARc2 but
downstream of their activator C/EBPb.
Results
DLK is expressed in adipose tissue and differentiating
adipocytes
Because DLK is expressed in a tissue-specific manner [22–24],
it has been proposed to serve as a regulator of differentiation. To
further characterize the function of DLK, we decided to
investigate whether this protein is involved in adipocyte differen-
tiation. This issue was first addressed by examining the protein
levels of DLK in the adipose organ, which is composed in
mammals of white and brown adipose tissues organized in various
subcutaneous or visceral depots. White adipose tissue is specialized
for lipid storage, whereas brown adipose tissue generates body
heat [25]. Immunoblot analysis of various white (gonadal,
retroperitoneal, omental, mesenteric and inguinal) and brown
(intrascapular) adipose depots showed that DLK is expressed to
high levels in both mesenteric white adipose and brown adipose
tissue. In comparison, heart as well as gonadal, retroperitoneal,
omental and inguinal white adipose tissue depots expressed barely
detectable levels of DLK (Fig. 1 A). The presence of DLK in
differentiating adipocytes was then assessed in a widely used model
of adipogenesis, 3T3-L1 preadipocytes [8], that were induced to
differentiate for different periods of time (2, 4, 6, 8 or 10 days).
Differentiation of 3T3-L1 cells was confirmed by blotting total cell
lysates with antibodies directed against the two PPARc isoforms,
PPARc1 and PPARc2, and the mature adipocyte markers
adiponectin and fatty acid synthase (FAS) (Fig. 1B). Interestingly,
DLK expression in differentiating cells increased gradually until
reaching a plateau from day 6 to day 10 of differentiation (Fig. 1B),
and this increase paralleled that seen with the protein levels of
PPARc1, PPARc2 and adiponectin, . Moreover, an immuno-
complex kinase assay showed that DLK is active during
differentiation of 3T3-L1 (Fig. 1C), reflecting the accumulation
of DLK detected by immunobloting.
To explore the presence and activation of the MAPKs ERK,
JNK and p38 in differentiating adipocytes, immunoblot analyses
with antibodies specific to the phosphorylated, activated forms of
these proteins were also performed. As shown in Fig. 1D, ERK
was inactive in undifferentiated cells but became active from day 2
of differentiation onward. On the other hand, our results also
demonstrated that JNK and p38 exist as constitutively phosphor-
ylated proteins in 3T3-L1 preadipocytes, and upon differentiation
of the cells, p38 activity progressively decreased while JNK activity
increased to reach a maximum at day 4. Immunoblots processed
in parallel with antibodies insensitive to the phosphorylation state
of these MAPKs demonstrated that there was no apparent
difference in the expression of either ERK, p38 or JNK during
adipocyte differentiation, suggesting that their activity are
positively or negatively regulated by the differentiation inducers.
DLK is required for lipid accumulation in 3T3-L1 cells
To further characterize the role of DLK in adipogenesis, we
silenced its expression in 3T3-L1 preadipocytes by RNA
interference and stained cells for lipids with Oil Red O (ORO)
at day 6 of differentiation. Knockdown of DLK was accomplished
by infecting cells with a lentiviral vector carrying a short hairpin
RNA (shRNA) that targets mouse DLK mRNA (mDLK). To
exclude potential nonspecific effects, cells were also infected with
an empty lentiviral vector (EV) or a lentiviral vector expressing a
human DLK shRNA (hDLK). In some experiments, the vector for
hDLK had slight effect on DLK expression in 3T3-L1 cells, but
this was considered negligible when compared to cells infected
with the sh-mDLK lentivirus. As depicted in Figure 2A, the sh-
mDLK construct abolished almost completely DLK protein
expression, whereas the empty or sh-hDLK vector had no such
effect. The intracellular level of tubulin was also unaffected by any
of these constructs. ORO staining clearly demonstrated that there
was no obvious accumulation of lipids in DLK-depleted cells, as
opposed to control cells (Fig. 2B). Lack of lipid accumulation could
not be attributed to cell mortality, as preadipocyte-shaped
undifferentiated cells were still visible after 6 days of differentiation
(upper right corner, Fig 2B). Spectrophotometric analysis of the
extracted neutral lipids confirmed that DLK-depleted cells were
devoid of lipids when compared to cells infected with the control
lentiviruses (Fig. 2C).
Loss of DLK impairs expression of the master regulators
of adipogenesis C/EBPa and PPARc2
As a result of the finding that DLK depletion was inhibitory for
accumulation of lipids in 3T3-L1 cells, we next sought to
investigate whether the absence of DLK could disrupt the
transcription factor cascade that mediates adipocyte differentia-
tion. For this purpose, 3T3-L1 cells were infected with the empty
lentivirus or lentiviruses expressing mouse or human DLK shRNA
and induced to differentiate for 6 days. The expression levels of
four transcription factors known to be involved in adipogenesis,
namely C/EBPd, C/EBPb, C/EBPa and PPARc [26] were
measured every two days by Western blotting with specific
antibodies. As shown in Figure 3, cells infected with the sh-mDLK
lentivirus showed a marked reduction of DLK protein expression
compared with the control. This depletion of DLK proteins had
no effect on the expression of C/EBPb and C/EBPd, which are
induced early in the differentiation process [12]. In fact, both
factors were indeed detectable at day 2 and 4 of differentiation,
respectively, and decreased afterwards (Fig. 3). Interestingly,
immunoblot analysis also demonstrated that the knockdown of
DLK strongly reduced expression of two master regulators of
adipogenesis, C/EBPa [27] and the PPARc2 isoform [28], which
were induced as early as day 2 or day 4 of differentiation in cells
infected with the control lentiviruses (Fig. 3). Accordingly,
expression of the mature adipocyte markers adiponectin and
FAS was impaired in DLK-depleted cells compared with cells
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C/EBPa and PPARc2 was not attributable to a change in the
subcellular localization of C/EBPb, which is essential for their
expression [29], since the presence of C/EBPb in the nucleus was
confirmed by immunoblot analysis of nuclear and cytoplasmic
fractions (data not shown). Moreover, the activity of JNK, which
acts as a downstream effector of DLK signaling in various cell
types [24,30,31], was also not affected by DLK knockdown. Taken
together, these data suggest that the decrease of DLK not only
prevents the accumulation of lipids, but also disrupts the whole
differentiation program of 3T3-L1 by impairing the normal
expression of C/EBPa and PPARc2.
DLK is required for expression of the C/EBPa, PPARc,
adiponectin and FAS genes
Since DLK depletion abrogated the accumulation of C/EBPa,
PPARc, adiponectin and FAS proteins in differentiating 3T3-L1
adipocytes, we next asked whether interruption of DLK signaling
would lead to decreased expression of their encoding genes. To do
this, we isolated total RNA from control or DLK-depleted cells at
day 0, 2, 4 or 6 of differentiation and analyzed the expression of the
C/EBPa, PPARc, adiponectin and FAS genes by quantitative RT-
PCR (Fig. 4). For each gene examined during adipocyte
differentiation, we observed that the amount of mRNA fluctuated
in a pattern similar to that seen at the protein levels (Fig. 3). Hence,
in either EV-, hDLK- or mDLK-infected cells, the levels of C/
EBPb mRNA increased at day 2 of differentiation, like its protein
counterpart, followed by a slight decrease in more differentiated
3T3-L1 adipocytes (Fig. 4A). However, for C/EBPa, PPARc,
adiponectin and FAS mRNAs (Fig 4B to 4E), which are all induced
later in adipogenesis, no increase of their expression levels was
observed in mDLK-infected cells relative to control cells. These
results indicate that DLK is required for expression of the C/EBPa,
PPARc, adiponectin and FAS genes in differentiating adipocytes.
DLK depletion does not impair C/EBPb binding activity in
vivo
An important function of C/EBPb during adipocyte differen-
tiation is to directly activate expression of C/EBPa and PPARc2
[29,32]. Based on these data and our results showing that
Figure 1. Up-regulation of DLK expression and activity during 3T3-L1 adipocyte differentiation. (A) Homogenates of mouse heart, white
adipose tissue from various depots (gonadal, retroperitoneal, omental, mesenteric and inguinal) and brown adipose tissue (BAT) were subjected to
Western blot analysis with specific antibodies against DLK or GAPDH. (B) and (D) 3T3-L1 cells induced to differentiate for 2, 4, 6, 8 and 10 days were
lysed and subjected to immunoblotting analysis with antibodies to DLK, adiponectin, fatty acid synthase (FAS), PPARc, ERK, phospho-ERK, p38,
phospho-p38, JNK, phospho-JNK and tubulin as the loading control. The antibody raised against PPARc reveals the presence of both PPARc isoforms,
PPARc1 and PPARc2. (C) 3T3-L1 cells induced to differentiate for the indicated times were lysed for immunoprecipitation analysis with anti-DLK
antibody and subjected to an immunocomplex kinase assay using myelin basic protein (MBP) as a substrate. Diff: Days of differentiation. WB: Western
Blot.
doi:10.1371/journal.pone.0004743.g001
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next investigated by chromatin immunoprecipitation (ChIP) assays
the binding activity of endogenous C/EBPb to the C/EBPa and
PPARc2 promoters in 3T3-L1 cells infected with the different
lentiviral constructs. DNA fragments immunoprecipitated by C/
EBPb antibody at day 2 of differentiation, a time window where
C/EBPb expression peaked, were amplified by PCR using primers
covering C/EBPb binding sites within the C/EBPa and PPARc2
promoters. As shown in Fig. 5, we observed no change in C/EBPb
binding activity at both promoters after DLK depletion, suggesting
that loss of DLK does not impair C/EBPb’s ability to stimulate
transcription of C/EBPa and PPARc2 genes.
Activation of PPARc1 by rosiglitazone rescues adipocyte
differentiation of DLK-depleted 3T3-L1 cells
PPARc2 is a central regulator of adipogenesis [33], whose
expression at the mRNA and protein levels is down-regulated in
DLK-depleted 3T3-L1 cells. We therefore investigated whether the
inhibitory effect of DLK depletion on adipocyte differentiation was
specifically caused by prevention of the expression of PPARc2 and
C/EBPa. To do so, we tested whether rosiglitazone, a well known
PPARc ligand [34], could rescue differentiation of 3T3-L1 cells
afterDLKknockdown.3T3-L1cellswereinfected with the different
lentiviruses and then subjected to the differentiation protocol for 6
days in the presence of rosiglitazone. Addition of rosiglitazone to
mDLK-infected cells restored the characteristic lipid accumulation
associated with adipocyte differentiation, although not to the extent
seen in EV- and hDLK-infected cells (Fig. 6A). Spectrophotometric
quantification of the extracted lipids showed that rosiglitazone-
treated mDLK-infected cells accumulate approximately 75% of the
lipids that are found in control cells (Fig 6A). Rosiglitazone
treatment of DLK-depleted cells also rescued, at least in part, the
expression of C/EBPa, PPARc2, adiponectin and FAS, as revealed
by immunoblot analyses carried out at day 2, 4 and 6 of
differentiation (Fig. 6B). Unexpectedly, an increase in DLK levels
was also observed in rosiglitazone-treated control and DLK
knockdown adipocytes, suggesting the potential involvement of an
activated form of PPARc in DLK expression. Taken together, these
results indicate that rosiglitazone can overcome the inhibitory effect
of DLK depletion on adipocyte differentiation and suggest that the
loss of DLK principally inhibits the differentiation program of 3T3-
L1 cells by preventing the expression of PPARc2.
Discussion
Adipogenesis is a complex process governed by a wide range of
regulatory proteins, including transcription factors, kinases and
Figure 2. DLK depletion in 3T3-L1 impairs lipid accumulation in response to differentiation inducers. 3T3-L1 cells infected with an
empty lentiviral vector (EV) or with a lentivirus expressing human (hDLK) or mouse (mDLK) DLK shRNA were induced to differentiate for 6 days. After
differentiation, cells were subjected to Western blot analysis with an antibody directed against DLK (A) or stained for lipids with ORO and
photographed (B). As a control for protein loading, immunoblots were probed in parallel with an antibody specific for tubulin. The inset at the upper
right corner of each photograph represents unstained cells at a 206magnification. (C) Lipids extracted from ORO-stained cells were quantified by
spectrophotometry at 520 nm. The data represent the mean6SEM of three independent experiments, relative to control EV-infected cells.
doi:10.1371/journal.pone.0004743.g002
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family member DLK as a novel regulator of adipocyte
differentiation. Immunoblot analyses of various mouse adipose
depots indeed demonstrated that DLK was specifically expressed
in mesenteric white and brown adipose tissue, suggesting a role for
this protein in differentiation and function of particular adipocyte
subpopulations. Using the 3T3-L1 preadipocyte cell line as a
model, we then showed that the protein level of DLK gradually
Figure 3. Loss of DLK in 3T3-L1 cells prevents expression of C/EBPa, PPARc, adiponectin and fatty acid synthase proteins but not
that of C/EBPb. 3T3-L1 cells infected with an empty lentivirus, a lentivirus expressing human DLK shRNA (hDLK) or a lentivirus expressing mouse
DLK shRNA (mDLK) were induced to differentiate for the indicated times. After differentiation, cells were subjected to Western blot analysis with
specific antibodies against DLK, C/EBPb, C/EBPd, C/EBPa, PPARc, adiponectin, fatty acid synthase (FAS), phospho-JNK, JNK and Akt as the loading
control.
doi:10.1371/journal.pone.0004743.g003
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PPARc2, adiponectin and fatty acid synthase. This increase in
DLK expression was paralleled by either an increase or decrease
in phosphorylation of the MAPKs ERK, p38 and JNK, which are
recognized to have both positive and negative regulatory effects on
adipocyte differentiation [20]. Using gene silencing of DLK by
RNA interference, we demonstrated that this protein is essential
for lipid accumulation and expression of the two master regulators
of adipocyte differentiation, C/EBPa and PPARc2 [27,33,35]. In
agreement with this result, we found that DLK depletion was
accompanied by decreased expression of adiponectin and fatty
acid synthase that are downstream genes of C/EBPa, PPARc
[36,37] and SREBP-1c (sterol regulatory element binding protein
1 c), a transcription factor involved in fatty acid metabolism [38],
respectively. This effect was reversed by the PPARc agonist
rosiglitazone, suggesting that the absence of DLK does not impair
the capacity of an activated form of PPARc to promote
adipogenesis, and that DLK action takes place upstream of
PPARc. The capacity of ligand-activated PPARc to rescue
adipogenesis in DLK-depleted cells is in agreement with previous
work showing the relative contribution of the two different PPARc
isoforms, PPARc1 and PPARc2, to adipogenesis. In their study,
using engineered 3T3-L1 cells devoid of PPARc1 and PPARc2,
Ren et al. [28] demonstrated that only ectopic expression of
PPARc2 can induce adipocyte differentiation in the absence of
exogenous ligand. Although it is not clear why this difference is
observed, Werman and colleagues [35] reported that PPARc2
contains a constitutive activation function in the N-terminus that is
up to 10-fold stronger than that of PPARc1. Moreover, it has been
found that the N-terminus of PPARc2 binds a small protein,
termed PGC-2, itself having adipogenic action [39]. Thus,
combined to these findings, our results suggest that the absence
of DLK most likely prevents adipocyte conversion of 3T3-L1 cells
by impairing the expression of PPARc2.
Of particular interest was the finding that neither the expression
nor the nuclear localization of C/EBPb was affected by the loss of
DLK. This suggests that the early events in adipogenesis such as
CREB (cAMP response element binding protein) activation by
protein kinase A [40] and its consequent up-regulation of C/EBPb
remain unmodified under these conditions. RNA interference
Figure 4. Depletion of DLK in 3T3-L1 cells blocks expression of PPARc and C/EBPa at the mRNA levels. 3T3-L1 cells infected with an
empty lentivirus (EV), a lentivirus expressing human DLK shRNA (hDLK) or a lentivirus expressing mouse DLK shRNA (mDLK) were induced to
differentiate, and at the indicated times, total RNA was extracted. C/EBPb, C/EBPa, PPARc, adiponectin and FAS mRNA levels were analyzed by
quantitative RT-PCR with specific primers. The expression level of each gene was normalized to the level of the 36B4 housekeeping gene. Results are
expressed as fold induction of mRNA levels relative to cells harvested on day 0 and they are representative of at least three independent experiments.
doi:10.1371/journal.pone.0004743.g004
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on JNK activity during 3T3-L1 adipocyte differentiation.
Although surprising, since DLK has been identified as an
upstream activator of the JNK pathway [41], this result is not
entirely without precedent. Published data from overexpression
and RNA interference-mediated knockdown studies in other cell
systems, such as COS and NIH 3T3 cells, also support a role for
DLK in activation of the p38, ERK and Akt signaling pathways
[31,42]. Therefore, the possibility that an effector other than JNK
mediates the action of DLK during adipogenesis in 3T3-L1 cells
can not be excluded.
As demonstrated by the results of our RT-qPCR analyses, DLK
depletion affects the accumulation of C/EBPa, PPARc, adipo-
nectin and fatty acid synthase proteins during adipocyte
differentiation by directly down-regulating the expression of their
encoding genes. Because ChIP assays revealed no difference in C/
EBPb recruitment to the cebpa and pparc2 promoters before and
after DLK depletion, it is tempting to speculate that DLK action
in adipogenesis lies between C/EBPb DNA binding and initiation
of cebpa and pparc2 gene transcription. C/EBPb binding to the
cebpa and pparc2 promoters without being able to induce their
transcription is a naturally occurring process during adipogenesis.
Indeed, once induced by adipogenic stimuli, C/EBPb binds to the
cebpa and pparc2 promoters well before initiation of transcription
starts [12]. This is followed by recruitment of the Ini1, Brg1 and
Brm subunits of the chromatin-remodelling SWI/SNF complex
[43] at the pparc2 promoter, which leads to activation of pparc2
transcription. The resulting accumulation of PPARc2i sa
prerequisite to the expression of C/EBPa, since active PPARc2
has the ability to displace a repressive complex composed of
mSin3A/histone deacetylase (HDAC)1 from the cebpa promoter
[29]. Thus, if the SWI/SNF complex is not recruited to the pparc2
promoter, neither PPARc2 nor C/EBPa will be expressed during
adipogenesis, a phenomenon similar to what is seen in DLK-
depleted 3T3-L1 cells. Our observation that rosiglitazone
treatment restores, at least in part, the expression of C/EBPa in
DLK-depleted cells is consistent with the idea that PPARc
activation facilitates C/EBPa expression [28]. Thus, it is likely that
rosiglitazone-mediated activation of PPARc1 in DLK-depleted
cells is sufficient to displace the repressive mSin3A/HDAC1
complex from the cebpa promoter and allow the expression of C/
EBPa, which in turn induces PPARc2, the most potent regulator
of adipogenesis [44].
Another potential mechanism by which DLK depletion might
decrease PPARc2 and C/EBPa mRNA levels is by altering
phosphorylation of C/EBPb. This idea is supported by the fact
that C/EBPb has multiple phosphorylation sites, some of which
are involved in the regulation of DNA-binding activity [16], while
others are key determinants of its transactivation capacity [17]. Of
particular interest among them is threonine 188, a consensus
phosphorylation site for both ERK and glycogen synthase kinase 3
(GSK3) [16]. Mutation of this threonine to alanine disrupts C/
EBPb’s ability to activate C/EBPa expression, but not DNA
binding to C/EBP response element within the proximal promoter
[17]. The T188A mutation also makes C/EBPb incapable of
inducing adiponectin gene expression, probably as a result of loss
of C/EBPa expression. Taken together, these results imply that
phosphorylation of C/EBPb at threonine 188 is critical for
transcriptional activity in the context of the C/EBPa promoter.
Additional support for a role of phosphorylation in the control of
C/EBPb function also comes from the findings of Roy et al. who
recently demonstrated that MLK3 activates C/EBPb in response
to IFN-c by a mechanism involving decreased phosphorylation of
a specific serine residue within transactivation domain [45].
Therefore, even if C/EBPb binds the cebpa and pparc2 promoters
in DLK-depleted cells as efficiently as in control cells, a change in
its phosphorylation state that would impair its function or
interaction with transcriptional co-activators is also consistent
with our results.
In summary, the results presented in this report identify DLK, a
MLK family member, as one of the key regulators of adipocyte
differentiation. Although the exact mechanisms by which DLK
controls this process remain to be identified, DLK action most
likely takes place downstream of C/EBPb DNA-binding to the
cebpa and pparc2 promoters but upstream of transcription initiation
(Fig. 7).
Materials and Methods
Chemicals and antibodies
Dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), insulin,
protease inhibitors, the mouse monoclonal antibody raised against
a-tubulin and all others common reagents were purchased from
Sigma-Aldrich Ltd. (Saint Louis, MO, USA). Rosiglitazone was
purchased from Cayman Chemicals, via Cedarlane (Burlingont,
Ontario, Canada). The rabbit polyclonal antibody raised against
Figure 5. Knockdown of DLK does not interfere with the
binding of C/EBPb to the cebpa and pparc2 promoters. EV-, hDLK-
and mDLK-infected 3T3-L1 cells induced to differentiate for two days
were subjected to chromatin immunoprecipitation with an antibody
specific to C/EBPb. The precipitated chromatin was analyzed by
quantitative PCR using primers spanning the binding site of C/EBPb
within the cebpa and pparc2 promoters. The data represent the
mean6SEM of three independent experiments, relative to control EV-
infected cells.
doi:10.1371/journal.pone.0004743.g005
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with an empty lentiviral vector (EV) or with a lentivirus expressing human (hDLK) or mouse (mDLK) DLK shRNA were induced to differentiate for 6
days in the presence of 1 mM rosiglitazone. After differentiation, cells were stained for lipids with ORO and photographed. Lipids extracted from ORO-
stained cells were quantified by spectrophotometry at 520 nm. The data represent the mean6SEM of three independent experiments, relative to EV-
infected cells. (B) 3T3-L1 cells infected with an empty lentiviral vector (EV) or with a lentivirus expressing human (hDLK) or mouse (mDLK) DLK shRNA
were induced to differentiate for 2, 4 or 6 days in the presence of 1 mM rosiglitazone or DMSO (vehicule). After differentiation, cells were subjected to
Western blot analysis with antibodies directed against DLK, C/EBPb, C/EBPa, PPARc, adiponectin and FAS. As a control for protein loading,
immunoblots were probed in parallel with an antibody specific for tubulin.
doi:10.1371/journal.pone.0004743.g006
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rabbit polyclonal antibodies raised against JNK, phospho-JNK,
C/EBPa, C/EBPb, C/EBPd and PPARc were obtained from
Santa-Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The
rabbit polyclonal antibody raised against adiponectin was obtained
from Calbiochem (Mississaga, Ontario, Canada). The rabbit
polyclonal and mouse monoclonal antibodies raised against Erk,
phospho-Erk, p38 and phospho-p38 were obtained from Cell
Signaling Technology Inc. (Beverly, MA, USA). The monoclonal
antibody raised against fatty acid synthase (FAS) was obtained
from BD Biosciences (San-Jose, CA, USA).
Cell culture and differentiation
3T3-L1 and 293T cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) Bovine
Calf Serum (BCS), 100 U/ml penicillin and 100 mg/ml strepto-
mycin. To induce differentiation, two day-postconfluent cells were
fed with DMEM supplemented with 10% FBS, 1 mM dexameth-
asone, 0.5 mM IBMX and 5 mg/ml insulin for two days. Medium
was then changed for DMEM supplemented with 10% FBS and
5 mg/ml insulin. Medium was changed after two more days for
DMEM supplemented with 10% FBS, and replenished every two
days until harvesting. For rosiglitazone-induced activation of
PPARc, cells were induced to differentiate as stated above, with
addition of 1 mM of rosiglitazone for the whole differentiation
period.
Lentivirus production and infection of 3T3-L1 cells
293T cells were cotransfected with the envelope protein
expressing vector (pMD2.G, kindly provided by Dr. Didier Trono,
University of Geneva Medical School, Geneva, Switzerland), the
packaging protein expressing vector (psPAX2, kindly provided by
Dr. Didier Trono, University of Geneva Medical School, Geneva,
Switzerland) and with either the transfer pLKO.1 empty lentiviral
vector (Addgene), the pLKO.1-based lentiviral mouse DLK
shRNA vector (clone TRCN0000022572, Open Biosystems) or
the pLKO.1-based lentiviral human DLK shRNA vector (clone
TRCN0000000999, Open Biosystems) using FuGENE 6 trans-
fection reagent (Roche Diagnostics, Laval, Que ´bec, Canada).
Briefly, cells were incubated in DMEM supplemented with 10%
(v/v) FBS, antibiotics and transfection mix for 48 hours. Medium
containing lentiviruses was then collected, treated with polybrene
(8 mg/ml) and filtered. 24 hours prior infection, 3T3-L1 cells were
seeded at a density of 2.5610
4 cells/ml in 100-mm dishes. The
next day, medium was removed and 1 ml of lentiviral suspension
was added to the plates. Cells were incubated at 37uC with the
lentiviral suspension for 1 hour, and 8.5 ml of DMEM supple-
mented with 10% BCS and antibiotics were added. 24 hours later,
cells were washed once with PBS, and either trypsinised and
reseeded into four 60-mm dishes in DMEM supplemented with
10% FBS and 2 mg/ml puromycin for selection or used as is.
Media was changed every 2 days until cells reached confluency,
after which they were induced to differentiate as mentioned above.
Preparation of cell or tissue lysates and immunoblotting
Cells were lysed for 60 min at 4uC in lysis buffer (50 mM Tris-
HCl pH 7.4, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA,
0.2 mM sodium orthovanadate, 0.2 mM sodium fluoride, 1 mM
phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, and 1 mg/ml
aprotinin). Lysates were clarified by centrifugation (12 0006g for
10 min at 4uC) and the concentration of total protein in the
supernatant fraction was quantified by the modified Bradford
protein assay (Bio-Rad Laboratories, Mississauga, Ontario,
Canada). Several white and brown adipose depots provided by
the animal facility of our Department were collected from female
CD-1 mice. For preparation of the homogenates, the tissues were
washed with ice-cold phosphate-buffered saline after their
removal, quickly frozen in liquid nitrogen and ground to a fine
powder with a mortar and a pestle. The tissue powder was then
resuspended in the cell lysis buffer described above, incubated for
60 min at 4uC and clarified by centrifugation. Quantification of
the tissue lysates was also done by the modified Bradford protein
assay. For immunoblotting, equal amounts of proteins were
fractionated by SDS-polyacrylamide gel electrophoresis (PAGE)
and transferred onto polyvinylidene difluoride (PVDF) membranes
(Roche Diagnostics, Laval, Que ´bec, Canada) using a semidry
transfer apparatus (Bio-Rad Laboratories, Mississauga, Ontario,
Canada). Membranes were incubated overnight on a rotating
plate at 4uC in a solution containing 20 mM Tris, pH 7.5,
150 mM NaCl, 0.1% Tween-20 (TBS-T) supplemented with 5%
skim milk powder (w/v) and the primary antibody. Membranes
were washed two times in TBS-T before incubation in a solution
containing TBS-T, 5% skim milk powder (w/v) and the secondary
horseradish peroxidase-conjugated antibodies on a rotating plate
for 1 hour at room temperature. Membranes were washed two
more times in TBS-T before immunoreactive bands were detected
by enhanced chemiluminescence (ECL Plus Western blotting kit,
Amersham Pharmacia Biotech, Inc.).
Quantification and staining of lipids with Oil Red O
Treated cells were carefully washed two times with PBS at room
temperature and then fixed for 30 min with 10% formaldehyde in
PBS. Each dish was then rinsed three times with distilled water.
Lipid droplets were stained for 15 min at room temperature with a
freshly made and filtered working solution of 0,3% Oil Red O.
Cells were then washed once with 70% ethanol, twice with distilled
water and photographed. Lipid quantification was done by
incubating stained cells with gentle agitation for 5 min in a 4%
(v/v) solution of NP40 in isopropanol. Supernatant was then
analysed with a spectrophotometer at 520 nm.
Figure 7. Proposed model for the role of DLK in adipogenesis.
Early events in adipogenesis lead to the expression of C/EBPb and C/
EBPd (step 1), which then bind to the cebpa and pparc2 promoters (step
2). DLK (step 3) in turn appears to contribute to the subsequent
increase in the expression of PPARc and C/EBPa (step 4) by a
mechanism that remains to be identified. The latter two proteins then
direct the expression of various adipocyte-specific genes (step 5).
doi:10.1371/journal.pone.0004743.g007
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3T3-L1 cells at 0, 2, 4, 6, 8 or 10 days of differentiation were
homogenized in lysis buffer (50 mM Tris-HCl pH 7.4, 1% Triton
X-100, 150 mM NaCl, 5 mM EDTA, 0.2 mM sodium orthova-
nadate, 0.2 mM sodium fluoride, 1 mM phenylmethylsulfonyl
fluoride, 1 mg/ml leupeptin, and 1 mg/ml aprotinin). Lysates
were clarified by centrifugation and the concentration of total
protein in the supernatant fraction was quantified using the
modified Bradford protein assay (Bio-Rad Laboratories). Typical-
ly, 500 mg of protein extract were incubated overnight at 4uC with
constant rotation using DLK polyclonal antibody (Abgent, 1:100
dilution) and protein A–sepharose beads. After incubation, the
immunocomplexes were washed three times with lysis buffer and
three times with kinase buffer (10 mM Tris-HCl pH 7.4, 150 mM
NaCl, 10 mM MgCl2, 0.5 mM DTT, 0.1 mM phenylmethylsul-
fonyl fluoride, 0.2 mM sodium orthovanadate, 1 mg/ml leupep-
tin, 1 mg/ml aprotinin). Immunocomplex kinase assays were
performed by incubating the immune complexes in 40 ml of kinase
buffer containing 2.5 mCi of [c
32P]ATP (Amersham Pharmacia
Biotech Inc.), 25 mM ATP, and 1 mg of myelin basic protein as
substrate. Following 20 min incubation at 30uC, the reaction was
stopped by adding an appropriate volume of 66 SDS-PAGE
sample buffer and boiling for 5 min. Phosphorylated proteins were
visualized by autoradiography after fractionation by SDS-PAGE.
Chromatin immunoprecipitation
Each experiment was done with one confuent 100-mm dish of 2
days differentiated 3T3-L1 cells infected with an empty lentiviral
vector (Empty vector) or lentiviruses expressing mouse (mDLK) or
human (hDLK) shRNA. Briefly, infected cells were crosslinked for
10 min at room temperature with 1% formaldehyde in PBS. Cells
were then washed in PBS, resuspended in 200 ml of ChIP lysis
buffer [1% sodium dodecyl sulfate (SDS), 10 mM EDTA, 50 mM
Tris-HCl (pH 8.0), and protease inhibitors] and sonicated (60%
maximum output for 15 s with 3 min pause, 3 cycles; Branson
Sonifier Type 450 with microtip; Danbury, CT) in an ice bath.
The chromatin solution was diluted 10-fold in ChIP dilution buffer
(0.01% SDS; 1.1% Triton X-100; 1.2 mM EDTA; 16.7 mM Tris,
pH 8.1; 16.7 mM NaCl; and protease inhibitors). 5% of the lysate
was used for purification of total DNA. Each sample was
precleared by incubating with 2 mg salmon sperm DNA/protein
A-agarose 50% gel slurry (Roche Diagnostics, Laval, Quebec,
Canada) for 2 hours at 4uC. An aliquot of 10 mg of indicated
antibody (or no antibody for the control) was added and
immunoprecipitated at 4uC overnight. The immunoprecipitate
was collected using salmon sperm DNA/protein A-agarose and
washed sequentially with the following buffers: low-salt wash
buffer (0.1% SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tri-
HCl, pH 8.1; 150 mM NaCl); high-salt wash buffer (0.1% SDS;
1% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.1;
500 mM NaCl); LiCl wash buffer (0.25 M LiCl; 1% Nonidet P-40;
1% sodium deoxycholate; 1 mM EDTA; 10 mM Tris-HCl,
pH 8.1) and TE (10 mM Tris-HCl, pH 8.0; 1 mM EDTA).
DNA- protein cross-links were reversed by incubation at 65uC
overnight followed by proteinase K treatment. DNA was
recovered by purification with the Qiaquik PCR purification
column (Qiagen). Results were analysed by real-time PCR with
primers spanning C/EBPb binding site at the C/EBPa (forward:
59-TAGTGTTGGCTGGAAGTGGGTGACTTAGAGGC-39,
reverse:5 9-TTCTCCTGTGACTTTCCAAGGCGGTGAGTG-
39) and PPARc2( forward:5 9-TACGTTTATCGGTGTTTCAT-
39, reverse:5 9-TCTCGCCAGTGACCC-39) promoters.
Real-time quantitative reverse transcription PCR
Total RNA was extracted using Trizol reagent (Invitrogen,
Burlington, Ontario, Canada). Reverse transcription was done on
total RNA with random hexamers as primers and the Moloney
murine leukemia virus reverse transcriptase (Promega, Madison,
Wisconsin, USA). Quantitative Real Time PCR reactions were run
on an ABI 7500 (Applied Biosystems) apparatus and results were
analysed with SDS software (Applied Biosystems). Amplification
patterns were normalized on the 36B4 housekeeping gene. The
primer used for amplification were: forward:5 9-CGACCTG-
GAAGTCCAACTAC-39 and reverse:5 9-ATCTGCTGCATCT-
GCTTG-39 for 36B4, forward:5 9-GGACAAGCTGAGCGAC-
GAGTA-39 and reverse:5 9-CCGTCAGCTCCAGCACCTT-39 for
C/EBPb, forward:5 9-GCGCAAGAGCCGAGATAAAG-39 and
reverse:5 9-CACGGCTCAGCTGTTCCA-39 for C/EBPa, forward:
59-GCCCAGGCTTGCTGAACGTGAAG-39 and reverse:5 9-
CACGTGCTCTGTGACGATCTGCC-39 for PPARc, forward:
59-CATCCCAGGACATCCTGGCCACAATG-39 and reverse:5 9-
GGCCCTTCAGCTCCTGTCATTCCAAC-39 for adiponectin
and forward:5 9-GCTATGCAGATGGCTGTCTCTCCCAG-39
and reverse:5 9-GCAGCGCTGTTTACATTCCTCCCAGG-39
for fatty acid synthase.
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